0:00
16:38
SGLT2 inhibitors and GLP-1 receptor agonists now have well-established cardiovascular and renal benefits. What does this mean for their role in the management of type 2 diabetes? Justin Coleman chats with endocrinologist and clinical pharmacologist, Tilenka Thynne, about this and other updates to Therapeutic Guidelines Diabetes.
More episodes from "Australian Prescriber Podcast"
Don't miss an episode of “Australian Prescriber Podcast” and subscribe to it in the GetPodcast app.